欧维波雷克斯顿是一种口服奥雷克辛受体2-选择性激动剂,用于1型麻醉症
Yves Dauvilliers1,2, Giuseppe Plazzi3,4, Emmanuel Mignot5
1National Reference Network for Narcolepsy, Sleep and Wake Disorders Center, Department of Neurology, Gui de Chauliac Hospital, Montpellier, France.
The New England journal of medicine
|May 14, 2025
概括
在1型麻醉症患者中,oveporexton显著改善了清醒状态,并减少了嗜睡和触觉症. 这种口服的素受体2激动剂显示出治疗这种罕见的神经疾病的前景.
科学领域:
- 神经学 神经学
- 睡眠医学 睡眠医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 1型麻醉症的特征是高睡眠,原因是失去素神经元和随后的低素水平.
- 了解素系统对于开发向性麻醉治疗至关重要.
研究的目的:
- 为了评估oveporexton (TAK-861),一种素受体2-选择性激动剂的疗效和安全性,在麻醉症1型患者.
- 评估不同剂量治疗方案对重点麻醉症症状的影响.
主要方法:
- 进行了2期,随机的,安慰剂控制的试验.
- 参与者每天接受一次或两次剂量的oveporexton或安慰剂.
- 主要终点:在8周的保持清醒测试 (MWT) 中,睡眠延迟的平均变化.
主要成果:
- 与安慰剂相比,oveporexton在MWT上显著改善了所有测试剂量的睡眠延迟 (调整后P≤0.001).
- 在爱普沃思睡眠度量 (ESS) 评分上也观察到显著的改善 (调整后P≤0.004).
- 欧维波雷克斯顿在特定剂量方案中降低了每周发生的触角症 (调整后P<0.05).
结论:
- 在8周的时间内,oveporexton在改善清醒,减少嗜睡和降低1型麻醉症患者的触角症方面表现出显著的有效性.
- 这项研究支持oveporexton作为1型麻醉症的潜在治疗剂.
- 常见的不良事件包括失眠,尿急和频率,没有观察到肝毒性.
相关概念视频
01:24Sleep-Wake Cycles
1.2K
Sleep is an essential physiological process vital to maintaining overall well-being. The reticular activating system (RAS), a network of neurons in the brainstem, regulates wakefulness and sleep. While it may seem passive, sleep consists of distinct cycles, each with its unique characteristics and functions. Two key sleep phases are non-rapid eye movement (NREM) and rapid eye movement (REM).
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
NREM Sleep
NREM sleep comprises four progressive stages that seamlessly merge:
1.2K
01:07Narcolepsy
84
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
84
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
143
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
143
01:25Adrenergic Agonists: Indirect-Acting Agents
1.4K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.4K
01:30Adrenergic Agonists: Direct-Acting Agents
1.3K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
1.3K
01:22Opioid Receptors: Overview
415
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
415